37 results on '"Meszaros, Gergely"'
Search Results
2. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder
- Author
-
Özgen, Heval, Spijkerman, Renske, Noack, Moritz, Holtmann, Martin, Schellekens, Arnt S.A., van de Glind, Geurt, Banaschewski, Tobias, Barta, Csaba, Begeman, Alex, Casas, Miguel, Crunelle, Cleo L., Blanco, Constanza Daigre, Dalsgaard, Søren, Demetrovics, Zsolt, den Boer, Jacomine, Dom, Geert, Eapen, Valsamma, Faraone, Stephen V., Franck, Johan, González, Rafael A., Grau-López, Lara, Groenman, Annabeth P., Hemphälä, Malin, Icick, Romain, Johnson, Brian, Kaess, Michael, Kapitány-Fövény, Máté, Kasinathan, John G., Kaye, Sharlene S., Kiefer, Falk, Konstenius, Maija, Levin, Frances R., Luderer, Mathias, Martinotti, Giovanni, Matthys, Frieda I.A., Meszaros, Gergely, Moggi, Franz, Munasur-Naidoo, Ashmita P., Post, Marianne, Rabinovitz, Sharon, Ramos-Quiroga, Antoni, Sala, Regina, Shafi, Abu, Slobodin, Ortal, Staal, Wouter G., Thomasius, Rainer, Truter, Ilse, van Kernebeek, Michiel W., Velez-Pastrana, Maria C., Vollstädt-Klein, Sabine, Vorspan, Florence, Young, Jesse T., Yule, Amy, van den Brink, Wim, and Hendriks, Vincent
- Published
- 2020
3. Machining of slender workpieces subjected to time-periodic axial force: stability and chatter suppression
- Author
-
Beri, Bence, Meszaros, Gergely, and Stepan, Gabor
- Published
- 2021
- Full Text
- View/download PDF
4. PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic
- Author
-
Godinas, Laurent, Iyer, Keerthana, Meszaros, Gergely, Quarck, Rozenn, Escribano-Subias, Pilar, Vonk Noordegraaf, Anton, Jansa, Pavel, D’Alto, Michele, Luknar, Milan, Milutinov Ilic, Senka, Belge, Catharina, Sitbon, Olivier, Reis, Abílio, Rosenkranz, Stephan, Pepke-Zaba, Joanna, Humbert, Marc, and Delcroix, Marion
- Published
- 2021
- Full Text
- View/download PDF
5. As time goes by... 2022 versus 2011 ERS-CRC PHAROS survey on managing pulmonary arterial hypertension (PAH) in European expert centres
- Author
-
Torbicki, Adam, primary, Howard, Luke S, additional, Meszaros, Gergely, additional, Pepke-Zaba, Joanna, additional, Reis, Abilio, additional, Sitbon, Olivier, additional, and Delcroix On Behalf Of Pharos Investigators, Marion, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Pulmonary Hypertension International Survey of Health Impacts (PHISH): a global patient questionnaire
- Author
-
Newman, Joseph, primary, Sanderman, Isla, additional, Stone, Millicent, additional, Meszaros, Gergely, additional, Fischer, Gerald, additional, Pepke-Zaba, Joanna, additional, and Pulmonary Vascular Research Institute: Patien, ., additional
- Published
- 2023
- Full Text
- View/download PDF
7. European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology
- Author
-
Aktaa, Suleman, primary, Gale, Chris P., additional, Brida, Margarita, additional, Giannakoulas, George, additional, Kovacs, Gabor, additional, Adir, Yochai, additional, Benza, Raymond L., additional, Böhm, Michael, additional, Coats, Andrew, additional, D'Alto, Michele, additional, Escribano‐Subias, Pilar, additional, Ferrari, Pisana, additional, Galiè, Nazzareno, additional, Gibbs, J. Simon R., additional, Gin‐Sing, Wendy, additional, Hoeper, Marius M., additional, Humbert, Marc, additional, Lang, Irene M., additional, Maron, Bradley A., additional, Meszaros, Gergely, additional, Noordegraaf, Anton V., additional, Price, Laura C., additional, Pepke‐Zaba, Joanna, additional, Rådegran, Göran, additional, Reis, Abilio, additional, Sitbon, Olivier, additional, Torbicki, Adam, additional, Ulrich, Silvia, additional, Rosenkranz, Stephan, additional, and Delcroix, Marion, additional
- Published
- 2023
- Full Text
- View/download PDF
8. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)
- Author
-
Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M., Badagliacca, Roberto, Berger, Rolf M. F., Brida, Margarita, Carlsen, Jorn, Coats, Andrew J. S., Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S., Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G., Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M., Pepke-Zaba, Joanna, Quint, Jennifer K., Radegran, Goran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean-Luc, Noordegraaf, Anton Vonk, Delcroix, Marion, Rosenkranz, Stephan, Schwerzmann, Markus, Anh-Tuan Dinh-Xuan, Bush, Andy, Abdelhamid, Magdy, Aboyans, Victor, Arbustini, Eloisa, Asteggiano, Riccardo, Barbera, Joan-Albert, Beghetti, Maurice, Cikes, Maja, Condliffe, Robin, de Man, Frances, Falk, Volkmar, Fauchier, Laurent, Gaine, Sean, Galie, Nazzareno, Gin-Sing, Wendy, Granton, John, Grunig, Ekkehard, Hassoun, Paul M., Hellemons, Merel, and Cardiovascular Centre (CVC)
- Subjects
ENDOTHELIN-RECEPTOR ANTAGONIST ,Guidelines ,Pulmonary arterial hypertension ,Pulmonary hypertension ,Chronic thrombo-embolic pulmonary hypertension ,LONG-TERM OUTCOMES ,QUALITY-OF-LIFE ,Balloon pulmonary angioplasty ,Soluble guanylate cyclase stimulators ,Connective tissue disease ,CALCIUM-CHANNEL BLOCKERS ,Congenital heart disease ,RIGHT-VENTRICULAR DYSFUNCTION ,IMPROVES EXERCISE CAPACITY ,Endothelin receptor antagonists ,Lung transplantation ,PRESERVED EJECTION FRACTION ,EOSINOPHILIA-MYALGIA-SYNDROME ,Pulmonary endarterectomy ,Left heart disease ,Lung disease ,Prostacyclin receptor agonists ,Prostacyclin analogues ,AFFAIRS CLINICAL-ASSESSMENT ,Phosphodiesterase type 5 inhibitors ,CONTINUOUS INTRAVENOUS EPOPROSTENOL - Published
- 2022
9. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG)
- Author
-
Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M, Badagliacca, Roberto, Berger, Rolf M F, Brida, Margarita, Carlsen, Jørn, Coats, Andrew J S, Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S, Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G, Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M, Pepke-Zaba, Joanna, Quint, Jennifer K, Rådegran, Göran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean Luc, Vonk Noordegraaf, Anton, Delcroix, Marion, Rosenkranz, Stephan, and Nielsen, Jens Cosedis
- Subjects
Endothelin Receptor Antagonists ,Hypertension, Pulmonary/diagnosis ,Humans - Published
- 2022
10. Доклад ERS по хронической тромбоэмболической легочной гипертензии
- Author
-
Delcroix, Marion, Torbicki, Adam, Gopalan, Deepa, Sitbon, Olivier, Klok, Frederikus A., Lang, Irene, Jenkins, David, Kim, Nick H., Humbert, Marc, Jais, Xavier, Vonk Noordegraaf, Anton, Pepke-Zaba, Joanna, Brénot, Philippe, Dorfmuller, Peter, Fadel, Elie, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Jansa, Pavel, Madani, Michael, Matsubara, Hiromi, Ogo, Takeshi, Grunig, Ekkehard, D'Armini, Andrea, Galie, Nazzareno, Meyer, Bernhard, Corkery, Patrick, Meszaros, Gergely, Mayer, Eckhard, Simonneau, G. rald, Pulmonary medicine, and ACS - Pulmonary hypertension & thrombosis
- Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries by fibrotic intravascular material, in combination with a secondary microvasculopathy of vessels < 500 μm, leads to increased pulmonary vascular resistance and progressive right heart failure. The mechanism responsible for the transformation of red clots into fibrotic material remnants has not yet been elucidated. In patients with pulmonary hypertension, the diagnosis is suspected when a ventilation/perfusion lung scan shows mismatched perfusion defects, and confirmed by right heart catheterisation and vascular imaging. Today, in addition to lifelong anticoagulation, treatment modalities include surgery, angioplasty and medical treatment according to the localisation and characteristics of the lesions. This statement outlines a review of the literature and current practice concerning diagnosis and management of CTEPH. It covers the definitions, diagnosis, epidemiology, follow-up after acute pulmonary embolism, pathophysiology, treatment by pulmonary endarterectomy, balloon pulmonary angioplasty, drugs and their combination, rehabilitation and new lines of research in CTEPH. It represents the first collaboration of the European Respiratory Society, the International CTEPH Association and the European Reference Network-Lung in the pulmonary hypertension domain. The statement summarises current knowledge, but does not make formal recommendations for clinical practice.
- Published
- 2022
11. Internationale Konsenserklarung zu Screening, Diagnostik und Behandlung von Jugendlichen und Heranwachsenden mit Aufmerksamkeitsdefizit-/Hyperaktivitatsstorung und gleichzeitigen Storungen durch Substanzgebrauch
- Author
-
Ozgen, Heval, Spijkerman, Renske, Noack, Moritz, Holtmann, Martin, Schellekens, Arnt S.A., van de Glind, Geurt, Banaschewski, Tobias, Barta, Csaba, Begeman, Alex, Casas, Miguel, Crunelle, Cleo L., Daigre Blanco, Constanza, Dalsgaard, Søren, Demetrovics, Zsolt, den Boer, Jacomine, Dom, Geert, Eapen, Valsamma, Faraone, Stephen V., Franck, Johan, González, Rafael A., Grau-López, Lara, Groenman, Annabeth P., Hemphala, Malin, Icick, Romain, Johnson, Brian, Kaess, Michael, Kapitány-Fovény, Máté, Kasinathan, John G., Kaye, Sharlene S., Kiefer, Falk, Konstenius, Maija, Levin, Frances R., Luderer, Mathias, Martinotti, Giovanni, Matthys, Frieda I.A., Meszaros, Gergely, Moggi, Franz, Munasur-Naidoo, Ashmita P., Post, Marianne, Rabinovitz, Sharon, Ramos-Quiroga, J. Antoni, Sala, Regina, Shafi, Abu, Slobodin, Ortal, Staal, Wouter G., Thomasius, Rainer, Truter, Ilse, Van Kernebeek, Michiel W., Velez-Pastrana, Maria C., Vollstadt-Klein, Sabine, Vorspan, Florence, Young, Jesse T., Yule, Amy, Van Den Brink, Wim, Hendriks, Vincent, Adult Psychiatry, Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, Observerende Klinische wetenschappen, Psychiatrie, Faculteit van de Geneeskunde en Farmacie, Neuroprotectie & Neuromodulatie, and Onderzoeksgroep Geestelijke Gezondheid en Welbevinden
- Subjects
Adult ,Adolescent ,DEFICIT HYPERACTIVITY DISORDER ,Attention-deficit ,610 Medicine & health ,Comorbidity ,SERIOUS CARDIOVASCULAR EVENTS ,Adolescents ,Substance use disorder ,behavioral disciplines and activities ,GUANFACINE EXTENDED-RELEASE ,DOUBLE-BLIND ,mental disorders ,Attention Deficit Disorder with Hyperactivity/diagnosis ,ADHD ,Humans ,Mass Screening ,Central Nervous System Stimulants/therapeutic use ,COGNITIVE-BEHAVIORAL THERAPY ,Child ,SCHOOL-BASED TREATMENT ,Substance-Related Disorders/diagnosis ,disorder ,RANDOMIZED CONTROLLED-TRIAL ,hyperactivity ,Psychiatry and Mental health ,Attention-deficit/hyperactivity ,Consensus statement ,Human medicine ,FOLLOW-UP ,PHARMACOLOGICAL-TREATMENT - Abstract
\(\it Hintergrund:\) Eine Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindesalter stellt einen Risikofaktor für Substanzmissbrauch und Störungen durch Substanzgebrauch (Substance Use Disorder, SUD) in der Pubertät und dem (frühen) Erwachsenenalter dar. ADHS und SUD treten auch häufig bei therapiesuchenden Jugendlichen auf, was die Diagnosestellung und Therapie erschwert sowie mit schlechten Behandlungsergebnissen verbunden ist. Forschungsergebnisse über die Wirkung der Behandlung von ADHS im Kindesalter auf die Prävention von SUD im Jugendalter sind nicht eindeutig und Studien über die Diagnose und Behandlung von Jugendlichen mit ADHS und SUD sind selten. Daher reicht die verfügbare Evidenz allgemein nicht aus, um starke Behandlungsempfehlungen zu rechtfertigen. \(\it Fragestellung:\) Ziel dieser Arbeit war es, eine Konsenserklärung auf der Grundlage von wissenschaftlichen Daten und klinischen Erfahrungen zu erhalten. \(\it Methodik:\) Es wurde eine modifizierte Delphi-Studie durchgeführt, um basierend auf der Kombination von wissenschaftlichen Daten und klinischer Erfahrung mit einer multidisziplinären Gruppe von 55 Expert_innen aus 17 Ländern einen Konsens zu erzielen. Die Expert_innen wurden gebeten, eine Reihe von Aussagen über die Wirkung der Behandlung von ADHS im Kindesalter auf die SUD bei Jugendlichen sowie über das Screening, die Diagnostik und die Behandlung von Jugendlichen mit komorbidem ADHS und SUD zu bewerten. \(\it \(\it Ergebnisse:\) Nach drei iterativen Bewertungsrunden und der Anpassung von 37 Aussagen wurde ein Konsens über 36 dieser Aussagen erzielt, die sechs Bereiche repräsentieren: allgemein (\(\it n\) = 4), Risiko der Entwicklung einer SUD (\(\it n\) = 3), Screening und Diagnostik (\(\it n\) = 7), psychosoziale Behandlung (\(\it n\) = 5), pharmakologische Behandlung (\(\it n\) = 11) und komplementäre Behandlungen (\(\it n\) = 7). Der Einsatz von Routinescreenings auf ADHS wird bei adoleszenten Patient_innen in einer Suchtbehandlung ebenso wie Routinescreenings auf SUD bei jugendlichen Patient_innen mit ADHS in allgemeinpsychiatrischen Therapiesettings empfohlen. Langwirksame Stimulanzien werden als Behandlung der ersten Wahl von ADHS bei Jugendlichen mit gleichzeitiger ADHS und SUD empfohlen. Die Pharmakotherapie sollte vorzugsweise in psychosoziale Behandlung eingebettet werden. Die einzige nichtkonsentierte Aussage betraf die Notwendigkeit von Abstinenz vor Beginn einer pharmakologischen Behandlung bei Jugendlichen mit ADHS und gleichzeitigem SUD. Im Gegensatz zur Mehrheit verlangten einige Expert_innen eine vollständige Abstinenz vor Beginn einer pharmakologischen Behandlung, einige waren gegen die Verwendung von Stimulanzien bei der Behandlung dieser Patient_innen (unabhängig von Abstinenz), während einige sich gegen die alternative Anwendung von Bupropion aussprachen. \(\ Schlussfolgerungen:\) Diese internationale Konsenserklärung kann von Kliniker_innen und Patient_innen zusammen in einem gemeinsamen Entscheidungsprozess genutzt werden, um die besten Interventionen auszuwählen und die bestmöglichen Ergebnisse bei adoleszenten Patient_innen mit gleichzeitiger ADHS und SUD zu erzielen. \(\it Background:\) Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood. ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diagnosis and treatment and is associated with poor treatment outcomes. Research on the effect of treatment of childhood ADHD on the prevention of adolescent SUD is inconclusive, and studies on the diagnosis and treatment of adolescents with ADHD and SUD are scarce. Thus, the available evidence is generally not sufficient to justify robust treatment recommendations. \(\it Objective:\) The aim of the study was to obtain a consensus statement based on a combination of scientific data and clinical experience. \(\it Method:\) A modified Delphi study to reach consensus based upon the combination of scientific data and clinical experience with a multidisciplinary group of 55 experts from 17 countries. The experts were asked to rate a set of statements on the effect of treatment of childhood ADHD on adolescent SUD and on the screening, diagnosis, and treatment of adolescents with comorbid ADHD and SUD. \(\it Results:\) After 3 iterative rounds of rating and adapting 37 statements, consensus was reached on 36 of these statements representing 6 domains: general (\(\it n\) = 4), risk of developing SUD (\(\it n\) = 3), screening and diagnosis (\(\it n\) = 7), psychosocial treatment (\(\it n\) = 5), pharmacological treatment (\(\it n\) = 11), and complementary treatments (\(\it n\) = 7). Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings. Long-acting stimulants are recommended as the first-line treatment of ADHD in adolescents with concurrent ADHD and SUD, and pharmacotherapy should preferably be embedded in psychosocial treatment. The only remaining no-consensus statement concerned the requirement of abstinence before starting pharmacological treatment in adolescents with ADHD and concurrent SUD. In contrast to the majority, some experts required full abstinence before starting any pharmacological treatment, some were against the use of stimulants in the treatment of these patients (independent of abstinence), while some were against the alternative use of bupropion. \(\it Conclusion:\) This international consensus statement can be used by clinicians and patients together in a shared decision-making process to select the best interventions and to reach optimal outcomes in adolescent patients with concurrent ADHD and SUD.
- Published
- 2022
12. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
- Author
-
Humbert, Marc, Kovacs, Gabor, Hoeper, Marius M, Badagliacca, Roberto, Berger, Rolf MF, Brida, Margarita, Carlsen, Jørn, Coats, Andrew JS, Escribano-Subias, Pilar, Ferrari, Pisana, Ferreira, Diogenes S, Ghofrani, Hossein Ardeschir, Giannakoulas, George, Kiely, David G, Mayer, Eckhard, Meszaros, Gergely, Nagavci, Blin, Olsson, Karen M, Pepke-Zaba, Joanna, Quint, Jennifer K, Rådegran, Göran, Simonneau, Gerald, Sitbon, Olivier, Tonia, Thomy, Toshner, Mark, Vachiery, Jean-Luc, Vonk Noordegraaf, Anton, Delcroix, Marion, Rosenkranz, Stephan, ESC/ERS Scientific Document Group, Toshner, Mark [0000-0002-3969-6143], and Apollo - University of Cambridge Repository
- Subjects
Endothelin Receptor Antagonists ,Pulmonary and Respiratory Medicine ,lung disease ,diagnosis ,chronic thrombo-embolic pulmonary hypertension ,Hypertension, Pulmonary ,pulmonary endarterectomy ,prostacyclin receptor agonists ,guidelines ,treatment ,pulmonary hypertension ,left heart disease ,pulmonary arterial hypertension ,lung transplantation ,Humans ,610 Medicine & health ,Evidence-Based Medicine ,360 Soziale Probleme, Sozialdienste ,prostacyclin analogues ,congenital heart disease ,balloon pulmonary angioplasty ,connective tissue disease ,endothelin receptor antagonists ,phosphodiesterase type 5 inhibitors ,soluble guanylate cyclase stimulators ,Cardiology and Cardiovascular Medicine ,610 Medizin und Gesundheit ,Algorithms ,360 Social problems & social services - Published
- 2022
13. [Untitled]
- Author
-
��zgen, Heval, Spijkerman, Renske, Noack, Moritz, Holtmann, Martin, Schellekens, Arnt S. A., van de Glind, Geurt, Banaschewski, Tobias, Barta, Csaba, Begeman, Alex, Casas, Miguel, Crunelle, Cleo L., Daigre Blanco, Constanza, Dalsgaard, S��ren, Demetrovics, Zsolt, den Boer, Jacomine, Dom, Geert, Eapen, Valsamma, Faraone, Stephen V., Franck, Johan, Gonz��lez, Rafael A., Grau-L��pez, Lara, Groenman, Annabeth P., Hemph��l��, Malin, Icick, Romain, Johnson, Brian, Kaess, Michael, Kapit��ny-F��v��ny, M��t��, Kasinathan, John G., Kaye, Sharlene S., Kiefer, Falk, Konstenius, Maija, Levin, Frances R., Luderer, Mathias, Martinotti, Giovanni, Matthys, Frieda I. A., Meszaros, Gergely, Moggi, Franz, Munasur-Naidoo, Ashmita P., Post, Marianne, Rabinovitz, Sharon, Ramos-Quiroga, J. Antoni, Sala, Regina, Shafi, Abu, Slobodin, Ortal, Staal, Wouter G., Thomasius, Rainer, Truter, Ilse, van Kernebeek, Michiel W., Velez-Pastrana, Maria C., Vollst��dt-Klein, Sabine, Vorspan, Florence, Young, Jesse T., Yule, Amy, van den Brink, Wim, and Hendriks, Vincent
- Subjects
610 Medizin und Gesundheit - Abstract
Hintergrund: Eine Aufmerksamkeitsdefizit-/Hyperaktivit��tsst��rung (ADHS) im Kindesalter stellt einen Risikofaktor f��r Substanzmissbrauch und St��rungen durch Substanzgebrauch (Substance Use Disorder, SUD) in der Pubert��t und dem (fr��hen) Erwachsenenalter dar. ADHS und SUD treten auch h��ufig bei therapiesuchenden Jugendlichen auf, was die Diagnosestellung und Therapie erschwert sowie mit schlechten Behandlungsergebnissen verbunden ist. Forschungsergebnisse ��ber die Wirkung der Behandlung von ADHS im Kindesalter auf die Pr��vention von SUD im Jugendalter sind nicht eindeutig und Studien ��ber die Diagnose und Behandlung von Jugendlichen mit ADHS und SUD sind selten. Daher reicht die verf��gbare Evidenz allgemein nicht aus, um starke Behandlungsempfehlungen zu rechtfertigen. Fragestellung: Ziel dieser Arbeit war es, eine Konsenserkl��rung auf der Grundlage von wissenschaftlichen Daten und klinischen Erfahrungen zu erhalten. Methodik: Es wurde eine modifizierte Delphi-Studie durchgef��hrt, um basierend auf der Kombination von wissenschaftlichen Daten und klinischer Erfahrung mit einer multidisziplin��ren Gruppe von 55 Expert_innen aus 17 L��ndern einen Konsens zu erzielen. Die Expert_innen wurden gebeten, eine Reihe von Aussagen ��ber die Wirkung der Behandlung von ADHS im Kindesalter auf die SUD bei Jugendlichen sowie ��ber das Screening, die Diagnostik und die Behandlung von Jugendlichen mit komorbidem ADHS und SUD zu bewerten. Ergebnisse: Nach drei iterativen Bewertungsrunden und der Anpassung von 37 Aussagen wurde ein Konsens ��ber 36 dieser Aussagen erzielt, die sechs Bereiche repr��sentieren: allgemein (n = 4), Risiko der Entwicklung einer SUD (n = 3), Screening und Diagnostik (n = 7), psychosoziale Behandlung (n = 5), pharmakologische Behandlung (n = 11) und komplement��re Behandlungen (n = 7). Der Einsatz von Routinescreenings auf ADHS wird bei adoleszenten Patient_innen in einer Suchtbehandlung ebenso wie Routinescreenings auf SUD bei jugendlichen Patient_innen mit ADHS in allgemeinpsychiatrischen Therapiesettings empfohlen. Langwirksame Stimulanzien werden als Behandlung der ersten Wahl von ADHS bei Jugendlichen mit gleichzeitiger ADHS und SUD empfohlen. Die Pharmakotherapie sollte vorzugsweise in psychosoziale Behandlung eingebettet werden. Die einzige nichtkonsentierte Aussage betraf die Notwendigkeit von Abstinenz vor Beginn einer pharmakologischen Behandlung bei Jugendlichen mit ADHS und gleichzeitigem SUD. Im Gegensatz zur Mehrheit verlangten einige Expert_innen eine vollst��ndige Abstinenz vor Beginn einer pharmakologischen Behandlung, einige waren gegen die Verwendung von Stimulanzien bei der Behandlung dieser Patient_innen (unabh��ngig von Abstinenz), w��hrend einige sich gegen die alternative Anwendung von Bupropion aussprachen. Schlussfolgerungen: Diese internationale Konsenserkl��rung kann von Kliniker_innen und Patient_innen zusammen in einem gemeinsamen Entscheidungsprozess genutzt werden, um die besten Interventionen auszuw��hlen und die bestm��glichen Ergebnisse bei adoleszenten Patient_innen mit gleichzeitiger ADHS und SUD zu erzielen.
- Published
- 2021
- Full Text
- View/download PDF
14. Additional file 1 of PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic
- Author
-
Godinas, Laurent, Iyer, Keerthana, Meszaros, Gergely, Quarck, Rozenn, Escribano-Subias, Pilar, Vonk Noordegraaf, Anton, Jansa, Pavel, D’Alto, Michele, Luknar, Milan, Milutinov Ilic, Senka, Belge, Catharina, Sitbon, Olivier, Reis, Abílio, Rosenkranz, Stephan, Pepke-Zaba, Joanna, Humbert, Marc, and Delcroix, Marion
- Abstract
Additional file 1. English questionnaire of the survey.
- Published
- 2021
- Full Text
- View/download PDF
15. Additional file 2 of PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic
- Author
-
Godinas, Laurent, Iyer, Keerthana, Meszaros, Gergely, Quarck, Rozenn, Escribano-Subias, Pilar, Vonk Noordegraaf, Anton, Jansa, Pavel, D’Alto, Michele, Luknar, Milan, Milutinov Ilic, Senka, Belge, Catharina, Sitbon, Olivier, Reis, Abílio, Rosenkranz, Stephan, Pepke-Zaba, Joanna, Humbert, Marc, and Delcroix, Marion
- Abstract
Additional File 2. Complete results of the answers to the questionnaire.
- Published
- 2021
- Full Text
- View/download PDF
16. Life-time prevalence and psychosocial correlates of adolescent direct self-injurious behavior: A comparative study of findings in 11 European countries
- Author
-
Brunner, Romuald, Kaess, Michael, Parzer, Peter, Fischer, Gloria, Carli, Vladimir, Hoven, Christina W., Wasserman, Camilla, Sarchiapone, Marco, Resch, Franz, Apter, Alan, Balazs, Judith, Barzilay, Shira, Bobes, Julio, Corcoran, Paul, Cosmanm, Doina, Haring, Christian, Iosuec, Miriam, Kahn, Jean-Pierre, Keeley, Helen, Meszaros, Gergely, Nemes, Bogdan, Podlogar, Tina, Postuvan, Vita, Saiz, Pilar A., Sisask, Merike, Tubiana, Alexandra, Varnik, Airi, and Wasserman, Danuta
- Published
- 2014
- Full Text
- View/download PDF
17. The Association of Nonsuicidal Self-Injury with Quality of Life and Mental Disorders in Clinical Adolescents—A Network Approach
- Author
-
Gyori, Dora, primary, Farkas, Bernadett Frida, additional, Horvath, Lili Olga, additional, Komaromy, Daniel, additional, Meszaros, Gergely, additional, Szentivanyi, Dora, additional, and Balazs, Judit, additional
- Published
- 2021
- Full Text
- View/download PDF
18. ERS statement on chronic thromboembolic pulmonary hypertension
- Author
-
Delcroix, Marion, primary, Torbicki, Adam, additional, Gopalan, Deepa, additional, Sitbon, Olivier, additional, Klok, Frederikus A., additional, Lang, Irene, additional, Jenkins, David, additional, Kim, Nick H., additional, Humbert, Marc, additional, Jais, Xavier, additional, Vonk Noordegraaf, Anton, additional, Pepke-Zaba, Joanna, additional, Brénot, Philippe, additional, Dorfmuller, Peter, additional, Fadel, Elie, additional, Ghofrani, Hossein-Ardeschir, additional, Hoeper, Marius M., additional, Jansa, Pavel, additional, Madani, Michael, additional, Matsubara, Hiromi, additional, Ogo, Takeshi, additional, Grünig, Ekkehard, additional, D'Armini, Andrea, additional, Galie, Nazzareno, additional, Meyer, Bernhard, additional, Corkery, Patrick, additional, Meszaros, Gergely, additional, Mayer, Eckhard, additional, and Simonneau, Gérald, additional
- Published
- 2020
- Full Text
- View/download PDF
19. Direct Self-Injurious Behavior (D-SIB) and Life Events among Vocational School and High School Students
- Author
-
Horváth, Lili, primary, Balint, Maria, additional, Ferenczi-Dallos, Gyongyver, additional, Farkas, Luca, additional, Gadoros, Julia, additional, Gyori, Dora, additional, Kereszteny, Agnes, additional, Meszaros, Gergely, additional, Szentivanyi, Dora, additional, Velo, Szabina, additional, Sarchiapone, Marco, additional, Carli, Vladimir, additional, Wasserman, Camilla, additional, Hoven, Christina, additional, Wasserman, Danuta, additional, and Balazs, Judit, additional
- Published
- 2018
- Full Text
- View/download PDF
20. Self-injury and externalizing pathology: a systematic literature review
- Author
-
Meszaros, Gergely, primary, Horvath, Lili Olga, additional, and Balazs, Judit, additional
- Published
- 2017
- Full Text
- View/download PDF
21. Are Mental Health Effects of Internet Use Attributable to the Web-Based Content or Perceived Consequences of Usage? A Longitudinal Study of European Adolescents
- Author
-
Hökby, Sebastian, primary, Hadlaczky, Gergö, additional, Westerlund, Joakim, additional, Wasserman, Danuta, additional, Balazs, Judit, additional, Germanavicius, Arunas, additional, Machín, Núria, additional, Meszaros, Gergely, additional, Sarchiapone, Marco, additional, Värnik, Airi, additional, Varnik, Peeter, additional, Westerlund, Michael, additional, and Carli, Vladimir, additional
- Published
- 2016
- Full Text
- View/download PDF
22. Experimental UWB impulse transmission with receiver and transmitter built with discrete parts
- Author
-
Feher, Gabor, primary, Meszaros, Gergely, additional, Horvath, Robert, additional, Szabo, Gabor, additional, and Berceli, Tibor, additional
- Published
- 2015
- Full Text
- View/download PDF
23. Linearity improvement of microwave amplifiers by special harmonic loads
- Author
-
Meszaros, Gergely, primary and Berceli, Tibor, additional
- Published
- 2015
- Full Text
- View/download PDF
24. Simulations of air-gap mode filtering technique for radio over multimode fiber system
- Author
-
Cseh, Tamas, primary, Meszaros, Gergely, additional, Fekete, Gabor, additional, and Berceli, Tibor, additional
- Published
- 2014
- Full Text
- View/download PDF
25. Reduction of harmonics and noise of microwave oscillators
- Author
-
Meszaros, Gergely, primary and Berceli, Tibor, additional
- Published
- 2014
- Full Text
- View/download PDF
26. Life‐time prevalence and psychosocial correlates of adolescent direct self‐injurious behavior: A comparative study of findings in 11 European countries
- Author
-
Brunner, Romuald, primary, Kaess, Michael, additional, Parzer, Peter, additional, Fischer, Gloria, additional, Carli, Vladimir, additional, Hoven, Christina W., additional, Wasserman, Camilla, additional, Sarchiapone, Marco, additional, Resch, Franz, additional, Apter, Alan, additional, Balazs, Judith, additional, Barzilay, Shira, additional, Bobes, Julio, additional, Corcoran, Paul, additional, Cosmanm, Doina, additional, Haring, Christian, additional, Iosuec, Miriam, additional, Kahn, Jean‐Pierre, additional, Keeley, Helen, additional, Meszaros, Gergely, additional, Nemes, Bogdan, additional, Podlogar, Tina, additional, Postuvan, Vita, additional, Saiz, Pilar A., additional, Sisask, Merike, additional, Tubiana, Alexandra, additional, Varnik, Airi, additional, and Wasserman, Danuta, additional
- Published
- 2013
- Full Text
- View/download PDF
27. Carrier drawing-out power LED driver with cost-effective discrete parts
- Author
-
Szabo, Gabor, primary, Feher, Gabor, additional, Fekete, Gabor, additional, and Meszaros, Gergely, additional
- Published
- 2013
- Full Text
- View/download PDF
28. Spectral cleaning for oscillators
- Author
-
Ladvanszky, Janos, primary, Meszaros, Gergely, additional, and Fuzy, Csaba, additional
- Published
- 2012
- Full Text
- View/download PDF
29. PanoCAST: A Panoramic Multicasting System for Mobile Entertainment
- Author
-
Takacs, Barnabas, primary, Beregszaszi, Alex, additional, and Komaromi-Meszaros, Gergely, additional
- Published
- 2007
- Full Text
- View/download PDF
30. Excessive and pathological Internet use – Risk-behavior or psychopathology?
- Author
-
Kaess, Michael, Klar, Johanna, Kindler, Jochen, Parzer, Peter, Brunner, Romuald, Carli, Vladimir, Sarchiapone, Marco, Hoven, Christina W., Apter, Alan, Balazs, Judit, Barzilay, Shira, Bobes, Julio, Cozman, Doina, Gomboc, Vanja, Haring, Christian, Kahn, Jean-Pierre, Keeley, Helen, Meszaros, Gergely, Musa, George J., Postuvan, Vita, Saiz, Pilar, Sisask, Merike, Varnik, Peeter, Resch, Franz, and Wasserman, Danuta
- Subjects
education ,610 Medizin und Gesundheit ,3. Good health - Abstract
Pathological Internet use (but only with respect to gaming) is classified as mental disorder in the ICD-11. However, there is a large group of adolescents showing excessive Internet use, which may rather be considered adolescent risk-behavior. The aim was to test whether pathological and excessive Internet use should be considered as "psychopathology" or "risk-behavior". A representative, cross-sectional sample of 11.110 students from 10 European Union countries was analyzed. Structural equation models, including the factors "risk-behavior" and "psychopathology" and the variables excessive and pathological Internet use, were tested against each other. "Risk-behavior" was operationalized by several risk-behaviors (e.g. drug abuse, truancy, etc). "Psychopathology" included measures of several mental disorders (e.g. depression, hyperactivity, etc). Excessive Internet use was assessed as the duration and frequency of Internet use. Pathological Internet use was assessed with the Young Diagnostic Questionnaire (i.e., presence of addiction criteria). Excessive Internet use loaded on "risk-behavior" (λ = 0.484, p < .001) and on "psychopathology" (λ = 0.071, p < .007). Pathological Internet use loaded on "risk-behavior" (λ = 0.333, p < .001) and on "psychopathology" (λ = 0.852, p < .001). Chi-square tests determined that the loadings of excessive Internet use (χ2 (1) = 81.98, p < .001) were significantly stronger on "risk-behavior" than "psychopathology". Vice versa, pathological Internet use loaded significantly stronger on "psychopathology" (χ2 (1) = 107.10, p < .001). The results indicate that pathological Internet use should rather be considered as psychopathology. Excessive Internet use on the other hand, should be classified as adolescent risk-behavior.
31. ERS statement on chronic thromboembolic pulmonary hypertension
- Author
-
Xavier Jaïs, Hossein Ardeschir Ghofrani, Irene Lang, Takeshi Ogo, Olivier Sitbon, Marc Humbert, Gérald Simonneau, Marius M. Hoeper, Frederikus A. Klok, Joanna Pepke-Zaba, Marion Delcroix, Pavel Jansa, Gergely Meszaros, Deepa Gopalan, Peter Dorfmüller, Adam Torbicki, Philippe Brenot, Nick H. Kim, Eckhard Mayer, David J. Jenkins, Patrick Corkery, Ekkehard Grünig, Anton Vonk Noordegraaf, Andrea Maria D'Armini, Bernhard C. Meyer, Hiromi Matsubara, Elie Fadel, Michael M. Madani, Nazzareno Galiè, Delcroix, Marion, Torbicki, Adam, Gopalan, Deepa, Sitbon, Olivier, Klok, Frederikus A., Lang, Irene, Jenkins, David, Kim, Nick H., Humbert, Marc, Jais, Xavier, Vonk Noordegraaf, Anton, Pepke-Zaba, Joanna, Brénot, Philippe, Dorfmuller, Peter, Fadel, Elie, Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., Jansa, Pavel, Madani, Michael, Matsubara, Hiromi, Ogo, Takeshi, Grünig, Ekkehard, D'Armini, Andrea, Galie, Nazzareno, Meyer, Bernhard, Corkery, Patrick, Meszaros, Gergely, Mayer, Eckhard, and Simonneau, Gérald
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Hypertension, Pulmonary ,medicine.medical_treatment ,Endarterectomy ,Pulmonary Artery ,030204 cardiovascular system & hematology ,Balloon ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Angioplasty ,Occlusion ,Epidemiology ,medicine ,Humans ,business.industry ,Keywords Plus DUAL-ENERGY CT PERFUSED BLOOD-VOLUME QUALITY-OF-LIFE ARTERIAL-HYPERTENSION COMPUTED-TOMOGRAPHY ,medicine.disease ,Pulmonary hypertension ,Pulmonary embolism ,030228 respiratory system ,Chronic Disease ,Cardiology ,Pulmonary Embolism ,Complication ,business ,Perfusion ,Angioplasty, Balloon - Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries by fibrotic intravascular material, in combination with a secondary microvasculopathy of vessels
- Published
- 2021
32. Exploring the patient perspective in pulmonary hypertension.
- Author
-
Ford HJ, Brunetti C, Ferrari P, Meszaros G, Moles VM, Skaara H, Torbicki A, and Gibbs JSR
- Abstract
The global impacts of pulmonary hypertension (PH) were formally recognised in 1973 at the 1st World Health Organization meeting dedicated to primary pulmonary hypertension, held in Geneva. Investigations into disease pathogenesis and classification led to the development of numerous therapies over the ensuing decades. While the impacts of the disease have been lessened due to treatments, the symptoms and adverse effects of PH and its therapies on patients' wellbeing and mental health remain significant. As such, there is a critical need to enhance understanding of the challenges patients face on a global scale with respect to care access, multidimensional patient support and advocacy. In addition, thoughtful analysis of the potential benefits and utilisation of mechanisms for the incorporation of patient-reported outcomes into diagnosis and treatment plans is needed. A summary of these areas is included here. We present a report of global surveys of patient and provider experiences and challenges regarding care access and discuss possible solutions. Also addressed is the current state of PH patient associations around the world. Potential ways to enhance patient associations and enable them to provide the utmost support are discussed. A summary of relevant patient-reported outcome measures to assess health-related quality of life in PH is presented, with suggestions regarding incorporation of these tools in patient care and research. Finally, information on how current global threats such as pandemics, climate change and armed conflict may impact PH patients is offered, along with insights as to how they may be mitigated with advanced contingency planning., Competing Interests: Conflict of interest: H.J. Ford reports grants from United Therapeutics, Merck, Gossamer Bio, Janssen, Cereno and Enzyvant, consultancy fees from United Therapeutics, Merck, Enzyvant, Liquidia, Janssen and Gossamer Bio, and a leadership role with the Pulmonary Hypertension Association. C. Brunetti reports support for the present work from Pulmonary Hypertension Association (USA), consultancy fees from Bayer and Aerovate, support for attending meetings from Pulmonary Hypertension Association, and a leadership role with Pulmonary Hypertension Association. P. Ferrari has no potential conflicts of interest to disclose. G. Meszaros reports consultancy fees from PHA Europe, EU-PFF and ERN-Lung, payment or honoraria for lectures, presentations, manuscript writing or educational events from Patient Expert Center vzw, and support for attending meetings from ERS. V.M. Moles reports grants from Janssen, Acceleron Pharma, Axon Therapies, Keros Therapeutics and Sumitomo Pharma America/Parexel International LLC, support for attending meetings from Foresee Pharmaceutical, participation on a data safety monitoring board or advisory board with United Therapeutics and Gossamer Bio, and is Assistant Editor at ACC.org Section of Pulmonary Hypertension and Venous Thromboembolism. H. Skara reports participation on a data safety monitoring board or advisory board with Aerovate. A. Torbicki reports consultancy fees from Bayer, Gossamer, Janssen and MSD, payment or honoraria for lectures, presentations, manuscript writing or educational events from AOP, Bayer, Janssen, Pfizer, MSD and Ferrer, support for attending meetings from Pfizer, AOP and Ferrer, and participation on a data safety monitoring board or advisory board with Boston and Janssen. J.S.R. Gibbs reports consultancy fees from Acceleron, Aerovate, Actelion/Janssen, Gossamer Bio, LG Chem, Keros, Merck, Bial Labcorp and United Therapeutics, and participation on a data safety monitoring board or advisory board with Merck, Gossamer Bio, Bial Labcorp, Keros and Actelion., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
33. [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].
- Author
-
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, and Rosenkranz S
- Subjects
- Humans, Evidence-Based Medicine, Algorithms, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary therapy
- Published
- 2023
- Full Text
- View/download PDF
34. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
- Author
-
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, and Rosenkranz S
- Subjects
- Endothelin Receptor Antagonists, Humans, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary therapy
- Published
- 2022
- Full Text
- View/download PDF
35. ERS statement on chronic thromboembolic pulmonary hypertension.
- Author
-
Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, Jenkins D, Kim NH, Humbert M, Jais X, Vonk Noordegraaf A, Pepke-Zaba J, Brénot P, Dorfmuller P, Fadel E, Ghofrani HA, Hoeper MM, Jansa P, Madani M, Matsubara H, Ogo T, Grünig E, D'Armini A, Galie N, Meyer B, Corkery P, Meszaros G, Mayer E, and Simonneau G
- Subjects
- Chronic Disease, Endarterectomy, Humans, Pulmonary Artery, Angioplasty, Balloon, Hypertension, Pulmonary, Pulmonary Embolism
- Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism, either symptomatic or not. The occlusion of proximal pulmonary arteries by fibrotic intravascular material, in combination with a secondary microvasculopathy of vessels <500 µm, leads to increased pulmonary vascular resistance and progressive right heart failure. The mechanism responsible for the transformation of red clots into fibrotic material remnants has not yet been elucidated. In patients with pulmonary hypertension, the diagnosis is suspected when a ventilation/perfusion lung scan shows mismatched perfusion defects, and confirmed by right heart catheterisation and vascular imaging. Today, in addition to lifelong anticoagulation, treatment modalities include surgery, angioplasty and medical treatment according to the localisation and characteristics of the lesions.This statement outlines a review of the literature and current practice concerning diagnosis and management of CTEPH. It covers the definitions, diagnosis, epidemiology, follow-up after acute pulmonary embolism, pathophysiology, treatment by pulmonary endarterectomy, balloon pulmonary angioplasty, drugs and their combination, rehabilitation and new lines of research in CTEPH.It represents the first collaboration of the European Respiratory Society, the International CTEPH Association and the European Reference Network-Lung in the pulmonary hypertension domain. The statement summarises current knowledge, but does not make formal recommendations for clinical practice., Competing Interests: Conflict of interest: M. Delcroix reports grants and other (investigator, speaker and consultant fees received by the institution) from Actelion/J&J, other (investigator, speaker and consultant fees received by the institution) from Bayer, other (speaker and consultant fees received by the institution) from MSD, other (investigator fees received by the institution) from Reata, other (investigator and consultant fees received by the institution) from Bellarophon, other (consultant fees received by the institution) from Acceleron, outside the submitted work. Conflict of interest: A. Torbicki reports grants and personal fees for lectures and consultancy from Actelion/Janssen, Bayer and MSD, personal fees for lectures from AOP, personal fees for lectures and consultancy from Pfizer, outside the submitted work. Conflict of interest: D. Gopalan reports other (speaker fees) from Actelion/J&J, other (consultancy work and speaker fees) from Bayer, outside the submitted work. Conflict of interest: O. Sitbon reports grants, personal fees and non-financial support from Actelion Pharmaceuticals and MSD, grants from GlaxoSmithKline, personal fees from Bayer, Acceleron Pharmaceuticals, Gossamer Bio and Ferrer, outside the submitted work. Conflict of interest: F.A. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi-Sankyo, MSD and Actelion, the Dutch Heart Foundation and the Dutch Thrombosis association, outside the submitted work. Conflict of interest: I. Lang reports grants and personal fees from Actelion-Janssen and AOP Orphan Pharma, personal fees from Medtronic, Ferrer and United Therapeutics, outside the submitted work. Conflict of interest: D. Jenkins reports grants from Bayer, personal fees for advisory board work from Actelion, outside the submitted work. Conflict of interest: N.H. Kim reports personal fees for consultancy from Actelion, Bayer and Merck, outside the submitted work. Conflict of interest: M. Humbert reports grants and personal fees from Actelion and Bayer, personal fees from Acceleron, GSK, Merck, Novartis, AstraZeneca and Sanofi, outside the submitted work. Conflict of interest: X. Jais reports personal fees and non-financial support from Actelion and MSD, grants from Bayer, outside the submitted work. Conflict of interest: A. Vonk Noordegraaf is supported by the Netherlands CardioVascular Research Initiative (CVON-2012-08 PHAEDRA, CVON-2017-10 DOLPHIN-GENESIS) and the Netherlands Organization for Scientific Research (NWO-VICI: 918.16.610), has received speakers’ money from Johnson & Johnson and Ferrer in the past 3 years, and served as a member of the scientific advisory board of Morphogen-XI. Conflict of interest: J. Pepke-Zaba has received speaker fees and honoraria for consultations from Actelion, Merck and Bayer, and her institution received research and educational grants from Actelion and Merck. Conflict of interest: P. Brénot has nothing to disclose. Conflict of interest: P. Dorfmuller has nothing to disclose. Conflict of interest: E. Fadel has nothing to disclose. Conflict of interest: H-A. Ghofrani reports personal fees and other (consultancy fees) from Actelion, Bayer AG, GlaxoSmithKline, Novartis and Pfizer, other (consultancy fees) from Bellerophon Pulse Technologies and MSD, grants from Deutsche Forschungsgemeinschaft (DFG), during the conduct of the study. Conflict of interest: M.M. Hoeper reports personal fees for consultancy and lectures from Bayer AG, MSD, Actelion, Jansen, Acceleron and Pfizer, during the conduct of the study. Conflict of interest: P. Jansa reports other (investigator) from Actelion, personal fees and other (investigator) from Bayer Pharma AG and Reata Pharmaceuticals, personal fees from AOP and MSD, outside the submitted work. Conflict of interest: M. Madani reports personal fees for consultancy from Actelion and Wexler Surgical, outside the submitted work. Conflict of interest: H. Matsubara reports personal fees from Actelion Pharmaceuticals Japan, Ltd, AOP Orphan Pharmaceuticals AG, Bayer Yakuhin, Ltd, Pfizer Japan, Inc., Nippon Shinyaku, Co., Ltd, Kaneka Medix Corporation, GlaxoSmithKline Pharmaceuticals, Ltd and United Therapeutics Corporation, outside the submitted work. Conflict of interest: T. Ogo has nothing to disclose. Conflict of interest: E. Grünig reports fees for lectures and/or consultations from Actelion, Bayer AG, GSK, MSD, United Therapeutics and Pfizer, outside the submitted work. Conflict of interest: A. D'Armini reports personal fees from Actelion Phamaceuticals, Bayer AG and Merck Sharp & Dohme, outside the submitted work. Conflict of interest: N. Galie reports grants and personal fees from Actelion and Janssen, personal fees from Pfizer and Ferrer, outside the submitted work. Conflict of interest: B. Meyer reports personal fees for lectures from Bayer AG, outside the submitted work. Conflict of interest: P. Corkery has nothing to disclose. Conflict of interest: G. Meszaros reports personal fees from Actelion Pharmaceuticals, outside the submitted work. Conflict of interest: E. Mayer reports personal fees for lectures and consultancy from Actelion, Bayer and MSD, during the conduct of the study. Conflict of interest: G. Simonneau reports personal fees and non-financial support from Actelion, Bayer and MSD, outside the submitted work., (Copyright ©ERS 2021. For reproduction rights and permissions contact permissions@ersnet.org.)
- Published
- 2021
- Full Text
- View/download PDF
36. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder].
- Author
-
Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de Glind G, Banaschewski T, Barta C, Begeman A, Casas M, Crunelle CL, Daigre Blanco C, Dalsgaard S, Demetrovics Z, den Boer J, Dom G, Eapen V, Faraone SV, Franck J, González RA, Grau-López L, Groenman AP, Hemphälä M, Icick R, Johnson B, Kaess M, Kapitány-Fövény M, Kasinathan JG, Kaye SS, Kiefer F, Konstenius M, Levin FR, Luderer M, Martinotti G, Matthys FIA, Meszaros G, Moggi F, Munasur-Naidoo AP, Post M, Rabinovitz S, Ramos-Quiroga JA, Sala R, Shafi A, Slobodin O, Staal WG, Thomasius R, Truter I, van Kernebeek MW, Velez-Pastrana MC, Vollstädt-Klein S, Vorspan F, Young JT, Yule A, van den Brink W, and Hendriks V
- Subjects
- Adolescent, Adult, Child, Comorbidity, Humans, Mass Screening, Attention Deficit Disorder with Hyperactivity diagnosis, Attention Deficit Disorder with Hyperactivity epidemiology, Attention Deficit Disorder with Hyperactivity therapy, Central Nervous System Stimulants therapeutic use, Substance-Related Disorders diagnosis, Substance-Related Disorders epidemiology, Substance-Related Disorders therapy
- Abstract
International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder Abstract. Background: Childhood attention-deficit/hyperactivity disorder (ADHD) is a risk factor for substance misuse and substance use disorder (SUD) in adolescence and (early) adulthood. ADHD and SUD also frequently co-occur in treatment-seeking adolescents, which complicates diagnosis and treatment and is associated with poor treatment outcomes. Research on the effect of treatment of childhood ADHD on the prevention of adolescent SUD is inconclusive, and studies on the diagnosis and treatment of adolescents with ADHD and SUD are scarce. Thus, the available evidence is generally not sufficient to justify robust treatment recommendations. Objective: The aim of the study was to obtain a consensus statement based on a combination of scientific data and clinical experience. Method: A modified Delphi study to reach consensus based upon the combination of scientific data and clinical experience with a multidisciplinary group of 55 experts from 17 countries. The experts were asked to rate a set of statements on the effect of treatment of childhood ADHD on adolescent SUD and on the screening, diagnosis, and treatment of adolescents with comorbid ADHD and SUD. Results: After 3 iterative rounds of rating and adapting 37 statements, consensus was reached on 36 of these statements representing 6 domains: general ( n = 4), risk of developing SUD ( n = 3), screening and diagnosis ( n = 7), psychosocial treatment ( n = 5), pharmacological treatment ( n = 11), and complementary treatments ( n = 7). Routine screening is recommended for ADHD in adolescent patients in substance abuse treatment and for SUD in adolescent patients with ADHD in mental healthcare settings. Long-acting stimulants are recommended as the first-line treatment of ADHD in adolescents with concurrent ADHD and SUD, and pharmacotherapy should preferably be embedded in psychosocial treatment. The only remaining no-consensus statement concerned the requirement of abstinence before starting pharmacological treatment in adolescents with ADHD and concurrent SUD. In contrast to the majority, some experts required full abstinence before starting any pharmacological treatment, some were against the use of stimulants in the treatment of these patients (independent of abstinence), while some were against the alternative use of bupropion. Conclusion: This international consensus statement can be used by clinicians and patients together in a shared decision-making process to select the best interventions and to reach optimal outcomes in adolescent patients with concurrent ADHD and SUD.
- Published
- 2021
- Full Text
- View/download PDF
37. Potential salivary biomarkers and their genetic effects in a pilot study of adolescent boys with externalizing problems.
- Author
-
Angyal N, Halasz J, Meszaros G, Kovacs JK, Kruk E, and Nemoda Z
- Subjects
- Adolescent, Catechol O-Methyltransferase, Humans, Hydrocortisone analysis, Male, Pilot Projects, Saliva chemistry, Stress, Psychological, alpha-Amylases, Biomarkers analysis, Hypothalamo-Hypophyseal System, Mental Disorders diagnosis, Pituitary-Adrenal System
- Abstract
Aims: Beside the well-known stress response marker cortisol, salivary alpha-amylase is receiving increasing attention. Numerous studies have investigated the potential biomarker properties of cortisol mirroring abnormal hypothalamic-pituitary-adrenal axis activity in connection to both internalizing and externalizing behavior problems. The other major physiological system involved in stress reactivity, the sympathetic nervous system activity can be also measured by the surrogate marker of salivary alpha-amylase. Most of the studies applied a stressful situation to obtain inter-individual differences in stress-reactivity, although differences in the baseline level of cortisol have been also shown in relation to externalizing problems. To test the relevance of another (easier) biomarker, we selected to study baseline circadian salivary cortisol and alpha-amylase levels among adolescent boys with externalizing problems., Methods: Saliva samples were collected at 3 time-points (morning, noon, evening) during 3 consecutive days from 37 inpatient boys (mean age 12.4±1.0). Cortisol and alpha-amylase levels were measured by enzyme-linked immunosorbent and kinetic enzyme assays, respectively. Genetic variants in the hypothalamic-pituitary-adrenal axis and the norepinephrine transporter or catecholamine metabolizing enzymes were tested for potential moderating effects at these salivary biomarkers., Results: Saliva cortisol showed the classical diurnal fluctuation in boys with externalizing problems (possibly from a lower morning level), but it was not modified by the presence of either conduct, oppositional defiant or attention-deficit/hyperactivity disorder. The diurnal fluctuation of the salivary alpha-amylase levels was also typical, but the presence of conduct disorder was associated with significantly lower alpha-amylase activity (p=0.024) among boys with externalizing problems. The catechol-O-methyltransferase Val158Met (rs4680) polymorphism had an additional effect on salivary alpha-amylase: boys with homozygote genotypes had lower alpha-amylase activity at all 3 time-points compared to Val/Met heterozygotes (p=0.045)., Conclusions: Our preliminary data suggest that salivary alpha-amylase might be used to further characterize subgroups within externalizing problems, however, this biomarker might be modified by certain genetic polymorphisms.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.